Association of Omentin-1 with Oxidative Stress and Clinical Significances in Patients with Breast Cancer

Abstract

Purpose: Breast cancer (BC) is globally the main reason of cancer-related deaths in women. Omentin-1, an anti-inflammatory and antioxidant adipokine, plays different roles in tumorigenesis and anti-oncogenic pathways. In present study, we investigated the association of omentin-1 with oxidative stress and clinical significances in healthy controls and BC patients to assess the prognostic and diagnostic value of omentin-1 in this cancer. Methods: This case-control study included 88 BC patients and 86 healthy controls. The serum levels of omentin-1 were assessed by enzyme-linked immunosorbent assays methods. Also, total antioxidant capacity (TAC), total oxidant status (TOS) and malondialdehyde (MDA) serum levels were measured by spectrophotometer. quantitative real-time polymerase chain reaction (qRT-PCR) was applied to the measurement of gene expression of omentin-1. Results: the serum levels of omentin-1 were significantly lower in the BC patients compared to the healthy controls (P<0.001). Moreover, gene expression of omentin-1was significantly downregulated in the BC tissues compared to the adjacent normal tissues (P<0.001). Gene expression of omentin-1and its serum levels were significantly higher in grade I compared with grade II and III (P=0.001, P<0.001, respectively). Additionally, the serum levels of omentin-1 in the p53-positive BC patients were significantly higher than the p53-negative BC patients (P=0.001). There was an inverse correlation between the serum levels of MDA and TOS with the serum levels of omentin-1 (r=-0.436, r=-461, respectively). Conclusion: We conclude that omentin-1 may have a good prognostic and diagnostic roles in the BC patients and decreases oxidative stress in these patients.

Circulating Omentin-1 as a Biomarker at the Intersection of Postmenopausal Breast Cancer Occurrence and Cardiometabolic Risk: An Observational Cross-Sectional Study

“…The results of our study depicting lower omentin-1 in BC are in agreement with the results of three small case-control studies (N = 30 to 88 premenopausal and postmenopausal case participants) [25][26][27], which provided unadjusted associations due to their small sample size, and the results of a meta-analysis of the two previous studies examining the association of serum omentin-1 with BC occurrence [22,44]. Similar findings for lower omentin-1 levels have also been reported in other malignancies including renal cell cancer [45].…”

“…In agreement with a bulk of previous studies analyzing the associations of omentin-1 with cardiometabolic risk factors, we have found negative associations with anthropometric variables, such as BMI, WC, and fat mass; inflammatory biomarkers, such as hsCRP, TNF-α, and IL-6; metabolic and lipid markers, such as glucose, insulin, HOMA-IR, cholesterol, LDL-C, and triglycerides; and blood pressure The findings of our study may present practical and clinical value as omentin-1 could be used as a non-invasive screening and clinical tool of BC in postmenopausal women as well as a preventive and therapeutic target. Low circulating omentin-1 may signal lymph node invasion, negative hormonal receptor status, and increased cardiometabolic risk [25][26][27]63]. More importantly, from a preventive perspective, circulating omentin-1 may increase through weight loss, physical exercise, and the adoption of a healthy diet such as the MedDiet which was found to be a positive predictor of serum omentin-1 in line with another study [68,69].…”

“…Since dysregulated circulating omentin-1, an anti-inflammatory and pro-apoptotic adipokine has been reported in various solid tumors and obesity-associated metabolic disorders, we hypothesize that postmenopausal women with BC, an obesity-related cancer, may present aberrant circulating levels of omentin-1 that could be associated with cardiometabolic risk factors, such as metabolic, lipid, and inflammatory biomarkers. To date, only four small case-control studies have examined the association between serum omentin and BC [ 24 , 25 , 26 , 27 ] without exploring its association with clinicopathologic, cardiometabolic, inflammatory, and dietary biomarkers. Therefore, our main goal was to evaluate the association of serum omentin-1 with PBC in the context of a cross-sectional study, taking into consideration several clinicopathologic characteristics including serum tumor markers, as well as anthropometric, metabolic, dietary, and inflammatory variables in postmenopausal women with BC, benign breast neoplasms (BBL), and obesity, and in healthy control participants.…”

Serum Levels of Irisin and Omentin-1 in Breast Neoplasms and Their Association with Tumor Histology

“…Regarding cancer, although in vitro data have shown possible anticarcinogenic effects of this molecule, findings from clinical studies were contradictory, with most studies showing increased omentin-1 serum concentrations in cancer patients compared to disease-free controls (as reviewed in [ 51 ]). However, in a very recent study, omentin gene expression and circulating levels were lower in patients with breast cancer compared to healthy controls [ 12 ]. However, to the best of our knowledge, no previous study has assessed omentin-1 levels across the spectrum of proliferative diseases of the breast.…”

“…In clinical studies, serum omentin-1 levels were increased in patients with prostate [ 9 ] and colorectal [ 10 ] cancer and decreased in patients with renal cell cancer [ 11 ] compared to controls. Most recently, omentin gene expression and circulating levels were lower in patients with breast cancer compared to healthy controls [ 12 ]. However, no previous studies have explored its levels in benign diseases of the breast or in response to neoadjuvant chemotherapy.…”